Taysha Gene Therapies Long Term Debt 2020-2026 | TSHA
Taysha Gene Therapies long term debt from 2020 to 2026. Long term debt can be defined as the sum of all long term debt fields.
|
Taysha Gene Therapies Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2025 | $50 |
| 2024 | $44 |
| 2023 | $41 |
| 2022 | $38 |
| 2021 | $37 |
|
Taysha Gene Therapies Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2026-06-30 | $49 |
| 2026-03-31 | $49 |
| 2025-12-31 | $50 |
| 2025-09-30 | $51 |
| 2025-06-30 | $41 |
| 2025-03-31 | $42 |
| 2024-12-31 | $44 |
| 2024-09-30 | $43 |
| 2024-06-30 | $38 |
| 2024-03-31 | $41 |
| 2023-12-31 | $41 |
| 2023-09-30 | $39 |
| 2023-06-30 | $38 |
| 2023-03-31 | $38 |
| 2022-12-31 | $38 |
| 2022-09-30 | $38 |
| 2022-06-30 | $38 |
| 2022-03-31 | $37 |
| 2021-12-31 | $37 |
| 2021-09-30 | $28 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.652B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |